94 related articles for article (PubMed ID: 18054615)
1. Pilot trial of the rate of response, safety, and tolerability of temozolomide and oral VP-16 in patients with recurrent or treatment-induced malignant central nervous system tumors.
Terasaki M; Bouffet E; Katsuki H; Fukushima S; Shigemori M
Surg Neurol; 2008 Jan; 69(1):46-50. PubMed ID: 18054615
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
3. Temozolomide and oral VP-16 for children and young adults with recurrent or treatment-induced malignant gliomas.
Korones DN; Smith A; Foreman N; Bouffet E
Pediatr Blood Cancer; 2006 Jul; 47(1):37-41. PubMed ID: 16047359
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors.
Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R
J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma.
Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Mastrangelo S; Maurizi P; Migliorati R; Bertolini P; Pastore M; Colosimo C; Riccardi R
Eur J Cancer; 2010 Nov; 46(16):2943-9. PubMed ID: 20538454
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971.
van den Bent MJ; Taphoorn MJ; Brandes AA; Menten J; Stupp R; Frenay M; Chinot O; Kros JM; van der Rijt CC; Vecht ChJ; Allgeier A; Gorlia T;
J Clin Oncol; 2003 Jul; 21(13):2525-8. PubMed ID: 12829671
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
8. [Temozolomide in the treatment of recurrent malignant glioma].
Kobayashi H; Sawamura Y; Ishii N; Murata J; Iwasaki Y
No Shinkei Geka; 2006 Dec; 34(12):1241-7. PubMed ID: 17154070
[TBL] [Abstract][Full Text] [Related]
9. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
12. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
13. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma.
Kong DS; Lee JI; Kim WS; Son MJ; Lim DH; Kim ST; Park K; Kim JH; Eoh W; Nam DH
Oncol Rep; 2006 Nov; 16(5):1117-21. PubMed ID: 17016602
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
[TBL] [Abstract][Full Text] [Related]
15. Salvage chemotherapy with cyclophosphamide for recurrent temozolomide-refractory anaplastic astrocytoma.
Chamberlain MC; Tsao-Wei DD; Groshen S
Cancer; 2006 Jan; 106(1):172-9. PubMed ID: 16323194
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of temozolomide treatment in patients with high-grade glioma.
Oshiro S; Tsugu H; Komatsu F; Ohmura T; Ohta M; Sakamoto S; Fukushima T; Inoue T
Anticancer Res; 2009 Mar; 29(3):911-7. PubMed ID: 19414327
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of concurrent continuous Temozolomide (TMZ) and Tamoxifen (TMX) for recurrent malignant astrocytic gliomas.
Spence AM; Peterson RA; Scharnhorst JD; Silbergeld DL; Rostomily RC
J Neurooncol; 2004 Oct; 70(1):91-5. PubMed ID: 15527114
[TBL] [Abstract][Full Text] [Related]
18. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
19. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Rich JN; Desjardins A; Vredenburgh J; Gururangan S; Sathornsumetee S; Badruddoja M; McLendon R; Provenzale J; Herndon JE; Dowell JM; Burkart JL; Newton HB; Friedman AH; Friedman HS
Cancer; 2005 Oct; 104(7):1478-86. PubMed ID: 16088964
[TBL] [Abstract][Full Text] [Related]
20. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]